Mrd response in relapsed/refractory fl after obinutuzumab plus bendamustine or bendamustine alone in the gadolin trial

HIGHLIGHTS

• who: Christiane Pott from the University Hospital Schleswig-Holstein, Kiel, Germany have published the research work: MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial, in the Journal: (JOURNAL) of April/15,/2010
• what: The authors report assessment of minimal residual disease (MRD) status and its association with outcome in rituximab-refractory follicular (FL) in the randomized GADOLIN trial (NCT01059630). The study showed a statistically significant improvement in progression-free survival (PFS) and overall survival (OS) in the G-Benda arm compared with the Benda arm . The . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.